TOP > 外国特許検索 > BIOMARKER OF DEMENTIA WITH LEWY BODIES

BIOMARKER OF DEMENTIA WITH LEWY BODIES

外国特許コード F170008926
整理番号 (S2015-0752-N0)
掲載日 2017年1月19日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP056828
国際公開番号 WO 2016143703
国際出願日 平成28年3月4日(2016.3.4)
国際公開日 平成28年9月15日(2016.9.15)
優先権データ
  • 特願2015-044353 (2015.3.6) JP
発明の名称 (英語) BIOMARKER OF DEMENTIA WITH LEWY BODIES
発明の概要(英語) Cholesterol, desmosterol and a ratio of the levels thereof are usable as a blood biomarker of Alzheimer's disease, frontotemporal lobar degeneration or dementia with Lewy bodies.
特許請求の範囲(英語) [claim1]
1. Being the method of appraising the effect of the candidacy substance of the [rebi] small somatotype acknowledgment symptom remedy medicine,
The death moth terol in the blood of the non human animal before the candidacy physical prescribing (DES) level and cholesterol (CHO) the process which measures level and,
The process which measures the DES level and CHO level in the blood of the non human animal after the candidacy physical prescribing and,
By comparison with the DES level and CHO level in the blood of the non human animal before the description above candidacy physical prescribing, when at least one which is selected from DES level and CHO level in the blood of the non human animal after the description above candidacy physical prescribing rises, when there is a possibility the aforementioned candidacy substance being effective to [rebi] small somatotype acknowledgment symptom remedy, the process which offers index,
It includes, the aforementioned method.
[claim2]
2. Being the method of appraising the effect of the candidacy substance of the [rebi] small somatotype acknowledgment symptom remedy medicine,
The process which measures the DES level and CHO level in the blood of the first non human animal which the candidacy substance is not prescribed and,
The process which measures the DES level and CHO level in the blood of the second non human animal which the candidacy substance is prescribed and,
By comparison with the DES level and CHO level in the blood of the first non human animal which the aforementioned candidacy substance is not prescribed, when at least one which is selected from DES level and CHO level in the blood of the second non human animal which the aforementioned candidacy substance is prescribed is high, when there is a possibility the aforementioned candidacy substance being effective to [rebi] small somatotype acknowledgment symptom remedy, the process which offers index,
It includes, the aforementioned method.
[claim3]
3. Being the method of appraising the effect of the candidacy substance of the [rebi] small somatotype acknowledgment symptom remedy medicine,
The process which measures the DES level and CHO level in the blood of the subject before the candidacy physical prescribing and,
The process which measures the DES level and CHO level in the blood of the subject after the candidacy physical prescribing and,
By comparison with the DES level and CHO level in the blood of the subject before the description above candidacy physical prescribing, when at least one which is selected from DES level and CHO level in the blood of the subject after the description above candidacy physical prescribing rises, when there is a possibility the aforementioned candidacy substance being effective to [rebi] small somatotype acknowledgment symptom remedy, the process which offers index,
It includes, the aforementioned method.
[claim4]
4. Being the method of assisting the diagnosis of the [rebi] small somatotype acknowledgment symptom,
The process which measures the DES level and CHO level in the blood of the subject and,
By comparison with reference level, when at least one which is selected from DES level and CHO level in the blood of the aforementioned subject is low, when there is a possibility of being the [rebi] small somatotype acknowledgment symptom, the process which offers index,
It includes, the aforementioned method.
[claim5]
5. Being the method of diagnosing the [rebi] small somatotype acknowledgment symptom,
The process which measures the DES level and CHO level in the blood of the subject and,
By comparison with reference level, when at least one which is selected from DES level and CHO level in the blood of the aforementioned subject is low, the process which it decides that it is the [rebi] small somatotype acknowledgment symptom,
It includes, the aforementioned method.
[claim6]
6. Being the method of selecting the patient who can expect the curative effect of the candidacy substance of the [rebi] small somatotype acknowledgment symptom remedy medicine,
The process which measures the DES level and CHO level in the blood of the subject and,
By comparison with reference level, when at least one which is selected from DES level and CHO level in the blood of the aforementioned subject is low, when it is the patient who should prescribe the candidacy substance of the [rebi] small somatotype acknowledgment symptom, the process which offers index,
It includes, the aforementioned method.
[claim7]
7. The [rebi] small somatotype acknowledgment symptom, being the method of distinguishing the Alzheimer's disease and the frontal side head leaf denaturation symptom,
The process which measures the DES level and CHO level in the blood of the subject and,
(1) by comparison with reference level, when CHO level in the blood of the aforementioned subject is low, there is a possibility without of being the [arutsuhaima] type acknowledgment symptom or the frontal side head leaf denaturation symptom type acknowledgment symptom, being the [rebi] small somatotype acknowledgment symptom;
Or
(2) by comparison with reference level, when DES level in the blood of the aforementioned subject is low, at the same time, ratio of the DES level for CHO level (DES/CHO) there is no difference, there is a possibility without of being the [arutsuhaima] type acknowledgment symptom or the frontal side head leaf denaturation symptom type acknowledgment symptom, being the [rebi] small somatotype acknowledgment symptom,
With the process which offers index,
It includes, the aforementioned method.
[claim8]
8. The [rebi] small somatotype acknowledgment symptom, being the method of distinguishing the Alzheimer's disease and the frontal side head leaf denaturation symptom,
The process which measures the DES level and CHO level in the blood of the subject and,
(1) by comparison with reference level, when CHO level in the blood of the aforementioned subject is low, there is a possibility without of being the Alzheimer's disease or the frontal side head leaf denaturation symptom, being the [rebi] small somatotype acknowledgment symptom;
(2) by comparison with reference level, when DES level in the blood of the aforementioned subject is low, there is a possibility without of being the frontal side head leaf denaturation symptom, being the [rebi] small somatotype acknowledgment symptom or the Alzheimer's disease;
(3) by comparison with reference level, when DES level in the blood of the aforementioned subject is low, at the same time, there is no difference in DES/CHO, there is a possibility without of being the Alzheimer's disease or the frontal side head leaf denaturation symptom, being the [rebi] small somatotype acknowledgment symptom;
Or
(4) by comparison with reference level, when DES/CHO in the blood of the aforementioned subject is low, there is a possibility without of being the [rebi] small somatotype acknowledgment symptom or the frontal side head leaf denaturation symptom, being the Alzheimer's disease, that the process which offers index,
It includes, the aforementioned method.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NIIGATA UNIVERSITY
  • EISAI RANDD MANAGEMENT CO., LTD.
  • 発明者(英語)
  • IKEUCHI TAKESHI
  • KUWANO RYOZO
  • SATO YOSHIAKI
  • BERNIER FRANCOIS
国際特許分類(IPC)
指定国 (WO2016143703)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close